Open an account

Rani Therapeutics Holdings

RANI · NASDAQ

$0.6528+$0.0025 (+0.38%)TodayMarket closed ·
Prev close $0.6503

About RANI

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 69 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

Employees
69
Headquarters
San Jose, California
Listed
Jul 30, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
ranitherapeutics.com

RANI key statistics

Market cap
91.00M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
562.93K
Volume
459.12K
Open price
$0.66
High today
$0.6798
Low today
$0.6411
52 Week high
$3.87
52 Week low
$0.6126

Rani Therapeutics Holdings (RANI) at a glance

As of Oct 20, 2026, Rani Therapeutics Holdings (RANI) shares are priced at $0.6528, giving the company a market cap of 91.00M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.6411 and $0.6798. The current price is 1.8% above the day's low and 4.0% below its high.

Volume so far is 459.12K shares, in line with the average of 562.93K shares a day.

Over the past year Rani Therapeutics Holdings has ranged from $0.6126 to $3.87, and now sits 1% of the way up that range.

The average analyst price target is $7.34, 1025.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $7.34
Low
$5.05
Now
$0.6528
High
$11.55

RANI news

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Avi Kapoor

    Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings

  • Avi Kapoor

    Dow Gains Over 100 Points; American Express Increases 2025 Forecast

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

Similar companies

Companies in the same industry as Rani Therapeutics Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.